Document Detail

Bone mineral density in early breast cancer patients.
MedLine Citation:
PMID:  20429308     Owner:  NLM     Status:  MEDLINE    
PURPOSE: Recent data indicate that women with breast cancer receiving aromatase inhibitors (AIs) are at increase risk of osteoporosis. PATIENTS AND METHODS: We evaluated 263 patients in our study, 42 receiving AI (22 - Arimidex, 20 - Femara), 69 selective estrogen receptor modulater (SERM - Tamoxifen), in 72 the therapy with SERM was changed for AI and 80 were in follow-up without hormonal therapy. We measured BMD by whole-body densitometer Hologic explorer. BMD of proximal femur and L spine was measured and evaluated and in case of degenerative changes also the region of distal forearm. We evaluated T-score. 43. RESULTS: 35% of the patients had decline of BMD to T-score of osteoporosis and only 13.31% of patients had normal bone density. 53.13% of the treated patients had BMD level of osteoporosis versus 40.2% of untreated patients or patients treated for less than one year. 3.13% of treated patients had normal BMD versus 16.58% of untreated patients (p = 0.015). CONCLUSIONS: We confirm the influence of adjuvant AI therapy on decline of BMD in early breast cancer patients in our study. The bone loss was statistically significant in patients whose therapy lasted at least one year (Fig. 6, Ref. 20). Full Text (Free, PDF)
S Spanik; B Spanikova
Related Documents :
11380558 - Immunophenotypic analysis of simultaneous specimens from different sites from the same ...
16410668 - High risk of osteopenia and bone derangement in postsurgical patients with craniopharyn...
20429308 - Bone mineral density in early breast cancer patients.
10952108 - Axial bone mineral density in patients with acromegaly.
9834338 - Portal vein thrombosis in cirrhosis with variceal hemorrhage.
1601008 - Transient igg subclass deficiencies in newly diagnosed diabetic children.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Bratislavsk? lek?rske listy     Volume:  111     ISSN:  0006-9248     ISO Abbreviation:  Bratisl Lek Listy     Publication Date:  2010  
Date Detail:
Created Date:  2010-04-30     Completed Date:  2010-05-18     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0065324     Medline TA:  Bratisl Lek Listy     Country:  Slovakia    
Other Details:
Languages:  eng     Pagination:  27-32     Citation Subset:  IM    
1st Dept of Clinical Oncology, Faculty of Medicine, Comenius University, Bratislava, Slovakia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Aromatase Inhibitors / therapeutic use*
Bone Density / drug effects*
Breast Neoplasms / drug therapy*
Chemotherapy, Adjuvant
Middle Aged
Postmenopause / metabolism
Tamoxifen / therapeutic use*
Reg. No./Substance:
0/Aromatase Inhibitors; 10540-29-1/Tamoxifen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Immunity profile in breast cancer patients.
Next Document:  Radionavigated detection of sentinel nodes in breast carcinoma--first experiences of our department.